Open Access

Correlative analysis of miR-34b and p53 with pathological characteristics of NSCLC

  • Authors:
    • Shuai Yang
    • Hongyan Zhu
    • Qingping Cheng
  • View Affiliations

  • Published online on: April 10, 2019     https://doi.org/10.3892/ol.2019.10239
  • Pages: 5558-5564
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The expression of miR-34b and p53 in non-small cell lung cancer (NSCLC) was investigated to explore its relationship with clinical pathology of NSCLC. Reverse transcription-quantitative PCR (RT-qPCR) method was used to quantitatively analyze miR-34b and p53 in cancer tissue and adjacent paraneoplastic (PTLC) tissue in 54 cases of NSCLC. The relationship between gene expression and clinical pathological data was analyzed. The expression of miR-34b in tumor tissues of NSCLC patients was significantly downregulated in comparison with PTLC. The expression level of miR-34b was negatively correlated with lymph node metastasis. It was positively correlated with the degree of differentiation and negatively correlated with the pathological stage (P<0.05). There was no significant association in the expression of miR-34b with age, sex, histological type, and gross classification (all P>0.05). The expression of p53 in the tumor tissue of NSCLC patients was significantly reduced in comparison with PTLC, and its expression was negatively correlated with the pathological stage, lymph node metastasis, and was positively correlated with the degree of differentiation. The expression of p53 in adenocarcinoma was generally higher than that of squamous cell carcinoma and large cell carcinoma. The expression of p53 in central type cancer was significantly higher than that in peripheral type (P<0.05). The expression of miR-34b and p53 was positively correlated in NSCLC tissues (r=0.797, P<0.001). The high expression of miR-34b and p53 is closely related to the clinical stage and pathological grade of NSCLC. miR-34b and p53 may serve as important tumor markers for NSCLC.

References

1 

Su Y, Wang Y, Zhou H, Lei L and Xu L: MicroRNA-152 targets ADAM17 to suppress NSCLC progression. FEBS Lett. 588:1983–1988. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Bahce I, Yaqub M, Smit EF, Lammertsma AA, van Dongen GA and Hendrikse NH: Personalizing NSCLC therapy by chara-cterizing tumors using TKI-PET and immuno-PET. Lung Cancer. 107:1–13. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Rotow J and Bivona TG: Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI

4 

Sanaei S, Hashemi M, Rezaei M, Hashemi SM, Bahari G and Ghavami S: Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk. Biomed Rep. 5:125–129. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Li H, Li X, Ge X, Jia L, Zhang Z, Fang R, Yang J, Liu J, Peng S, Zhou M, et al: MiR-34b-3 and miR-449a inhibit malignant progression of nasopharyngeal carcinoma by targeting lactate dehydrogenase A. Oncotarget. 7:54838–54851. 2016.PubMed/NCBI

6 

Hashemi M, Danesh H, Bizhani F, Narouie B, Sotoudeh M, Nouralizadeh A, Sharifiaghdas F, Bahari G and Taheri M: Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer. Cancer Biomark. 18:155–159. 2017. View Article : Google Scholar : PubMed/NCBI

7 

Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M and de Marinis F: Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacol Res. 117:406–415. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Comel A, Sorrentino G, Capaci V and Del Sal G: The cytoplasmic side of p53's oncosuppressive activities. FEBS Lett. 588:2600–2609. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Edwards T, Al-Najjar H, Crosbie P, Martin J, Chaturvedi A, Evison M and Booton R: 89P: Investigating the potential utility of the alternative IASLC nodal staging classification in NSCLC. J Thorac Oncol. 11 (Suppl):S94–S95. 2016. View Article : Google Scholar

10 

Yang X and Lin D: Changes of 2015 WHO Histological Classification of Lung Cancer and the clinical significance. Zhongguo Fei Ai Za Zhi. 19:332–336. 2016.(In Chinese). PubMed/NCBI

12 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

13 

Ma ZL, Hou PP, Li YL, Wang DT, Yuan TW, Wei JL, Zhao BT, Lou JT, Zhao XT, Jin Y, et al: MicroRNA-34a inhibits the proliferation and promotes the apoptosis of non-small cell lung cancer H1299 cell line by targeting TGFβR2. Tumour Biol. 36:2481–2490. 2015. View Article : Google Scholar : PubMed/NCBI

14 

Wang R, Chen XF and Shu YQ: Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics. Am J Cancer Res. 5:32–51. 2014.PubMed/NCBI

15 

Hu Z, Hou D, Wang X, You Z and Cao X: TSPAN12 is overexpressed in NSCLC via p53 inhibition and promotes NSCLC cell growth in vitro and in vivo. Onco Targets Ther. 11:1095–1103. 2018. View Article : Google Scholar : PubMed/NCBI

16 

Lin X, Xu XY, Chen QS and Huang C: Clinical significance of microRNA-34a in esophageal squamous cell carcinoma. Genet Mol Res. 14:17684–17691. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Chen LL, Shen Y, Zhang JB, Wang S, Jiang T, Zheng MQ, Zheng ZJ and Chen CX: Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma. Genet Mol Res. 15:152016. View Article : Google Scholar

18 

Tian Q, Jia J, Ling S, Liu Y, Yang S and Shao Z: A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol. 40:67–72. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Hu L, Ai J, Long H, Liu W, Wang X, Zuo Y, Li Y, Wu Q and Deng Y: Integrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancer. Oncotarget. 7:8441–8454. 2016.PubMed/NCBI

20 

Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, et al: A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget. 7:37250–37259. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Balça-Silva J, Sousa Neves S, Gonçalves AC, Abrantes AM, Casalta-Lopes J, Botelho MF, Sarmento-Ribeiro AB and Silva HC: Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res. 32:1603–1609. 2012.PubMed/NCBI

22 

Kerr KM and López-Ríos F: Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann Oncol. 27:16–24. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al: PDL1 regulation by p53 via miR-34. J Natl Cancer Inst. 108:v3032015.

24 

Wang Z, Chen Z, Gao Y, Li N, Li B, Tan F, Tan X, Lu N, Sun Y, Sun J, et al: DNA hypermethylation of microRNA-34b/c has prognostic value for stage I non-small cell lung cancer. Cancer Biol Ther. 11:490–496. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yang, S., Zhu, H., & Cheng, Q. (2019). Correlative analysis of miR-34b and p53 with pathological characteristics of NSCLC. Oncology Letters, 17, 5558-5564. https://doi.org/10.3892/ol.2019.10239
MLA
Yang, S., Zhu, H., Cheng, Q."Correlative analysis of miR-34b and p53 with pathological characteristics of NSCLC". Oncology Letters 17.6 (2019): 5558-5564.
Chicago
Yang, S., Zhu, H., Cheng, Q."Correlative analysis of miR-34b and p53 with pathological characteristics of NSCLC". Oncology Letters 17, no. 6 (2019): 5558-5564. https://doi.org/10.3892/ol.2019.10239